Skip to main content

Advertisement

SpringerLink
Log in

Viral Skin Infections in the Elderly

Diagnosis and Management

  • Therapy In Practice
  • Published:
Drugs & Aging Aims and scope Submit manuscript

Abstract

Over the past several years, there have been advances in the diagnosis and treatment of cutaneous viral diseases in elderly patients. Herpes zoster is caused by reactivation in adults of the varicella-zoster virus (VZV) that causes chickenpox in children. For many years, aciclovir was the gold standard of antiviral therapy for the treatment of herpes zoster. Famciclovir and valaciclovir are newer antivirais, which offer less frequent administration. Postherpetic neuralgia (PHN) refers to pain lasting 2 months or more after an acute attack of herpes zoster. The pain may be constant or intermittent. The treatment of established PHN may include topical anaesthetics, analgesics, tricyclic antidepressants and anticonvulsants, and nonpharmacological therapy may be used to complement such treatment. Therapeutic strategies to prevent PHN include the use of oral corticosteroids, nerve blocks, and treatment with standard antiviral therapy.

The three most recently discovered human herpes viruses (HHV-6, HHV-7 and HHV-8), in common with the other members of the family, may cause a primary infection, establish latent infection in a specific set of cells in their host, and then reactivate if conditions of altered immunity develop. These viruses have been associated with an array of disorders, which are important for the clinician to recognise.

Cytomegalovirus (CMV) is a member of the herpesvirus family that is very prevalent worldwide. More than 80% of primary infections and 20% of reactivation-producing symptoms occur in transplant populations. Treatment options include intravenous administration of ganciclovir, foscarnet or cidofovir.

Herpes simplex virus (HSV) most commonly affects the genital and perioral regions. In the elderly, HSV infection is typically manifest at the vermilion border of the lip. The main concern of recurrent herpes labialis in the elderly is related to potential autoinoculation of the eye or genital area. Treatment with aciclovir, famciclovir or valaciclovir is indicated for these infections.

Molluscum contagiosum is caused by a poxvirus, which produces cutaneous lesions that appear as small, firm, umbilicated papules. Immunocompromised patients often do not respond to the usual destructive therapies, and intravenous or topical cidofovir may be useful in these patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I

Similar content being viewed by others

References

  1. Beutner KR. Clinical management of herpes zoster in the elderly patient. Compr Ther 1996, 6(22): 183–6

    Google Scholar 

  2. Soong SJ, Whitley R. A comprehensive analysis of the effect of acyclovir versus placebo on herpes zoster pain. Presented during the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1995 Sep 17–20; San Francisco (CA)

  3. Tyring SK. Efficacy of famciclovir in the treatment of herpes zoster. Semin Dermatol 1996; 15: 27–31

    PubMed  CAS  Google Scholar 

  4. Degreef H, Famciclovir Herpes Zoster Clinical Study Group. Famciclovir, a new oral antiherpes drug: results of the first controlled clinical study demonstrating its efficacy and safety in the treatment of uncomplicated herpes zoster in immunocompetent patients. Int J Antimicrob Agents 1994; 4: 241–6

    Article  PubMed  CAS  Google Scholar 

  5. Tyring S, Barbarash R, Nahlik J, et al. Famciclovir for the treatment of acute herpes zoster effects on acute disease and postherpetic neuralgia. Ann Intern Med 1995; 123: 89–96

    PubMed  CAS  Google Scholar 

  6. Beutner K, Friedman DJ, Forszpaniak C, et al. Valciclovir compared with acyclovir for improved therapy for herpes zoster in immunocompetent adults. Antimicrob Agents Chemother 1995; 39: 1546–53

    Article  PubMed  CAS  Google Scholar 

  7. Gibney MD, Nahass GT, Leonardi CL. Cutaneous reactions following herpes zoster infections: report of three cases and a review of the literature. Br J Dermatol 1996; 134: 504–9

    Article  PubMed  CAS  Google Scholar 

  8. Aloi FG, Appino A, Puiatt P. Lymphoplasmocytoid lymphoma arising in herpes zoster scars. J Am Acad Dermatol 1990; 22: 130–1

    Article  PubMed  CAS  Google Scholar 

  9. Niedt GW, Prioleau PG. Kaposi’s sarcoma in a dermatome previously involved by herpes zoster. J Am Acad Dermatol 1988; 18: 448–51

    Article  PubMed  CAS  Google Scholar 

  10. Serfling U, Penneys NS, Zhu WY, et al. Varicella-zoster virus DNA in granulomatous skin lesions following herpes zoster. J Cutan Pathol 1993; 20: 28–33

    Article  PubMed  CAS  Google Scholar 

  11. Epstein W, Fukuyama K. Mechanisms of granulomatous inflammation. Immunol Ser 1989; 46: 687–721

    PubMed  CAS  Google Scholar 

  12. Guill MA, Goette DK. Granuloma annulare at sites of healing herpes zoster. Arch Dermatol 1978; 114: 1383

    Article  PubMed  CAS  Google Scholar 

  13. Packer RH, Fields JP, King LE. Granuloma annulare in herpes zoster scars. Cutis 1984; 34: 177–9

    PubMed  CAS  Google Scholar 

  14. Bisaccia E, Scarborough DA, Carr RD. Cutaneous sarcoid granuloma formation in herpes zoster scars. Arch Dermatol 1983; 119: 788–9

    Article  PubMed  CAS  Google Scholar 

  15. Wright AL, Cotton DWK, Winfield DA, et al. Granuloma formation in herpes zoster scars. Dermatologica 1989; 179: 45–6

    Article  PubMed  CAS  Google Scholar 

  16. Kost RG, Straus SE. Postherpetic neuralgia: pathogenesis, treatment, and prevention. N Engl J Med 1996; 335: 32–42

    Article  PubMed  CAS  Google Scholar 

  17. Ragozzino MW, Mellon LJ, Kurland LT, et al. Population-based study of herpes zoster and its sequelae. Medicine (Baltimore) 1982; 61: 310–6

    CAS  Google Scholar 

  18. De Moragas JM, Kierland RR. The outcome of patients with herpes zoster. Arch Dermatol 1957; 75: 193–6

    Article  Google Scholar 

  19. Epstein E. Treatment of zoster and postzoster neuralgia by the intralesional infection of triamcinolone: a computer analysis of 199 cases. Int J Dermatol 1976; 15: 762–9

    Article  PubMed  CAS  Google Scholar 

  20. Balfour HH. Varicella zoster virus infections in immunocompromised hosts: a review of the natural history and management. Am J Med 1998; 85: 68–73

    Google Scholar 

  21. Rogers RS, Tindall JP. Geriatric herpes zoster. J Am Geriatr Soc 1971; 19: 495–504

    PubMed  Google Scholar 

  22. Clemmensen OJ, Andersen KE. ACTH versus prednisone and placebo in herpes zoster treatment. Clin Exp Dermatol 1984; 9: 557–63

    Article  PubMed  CAS  Google Scholar 

  23. Hope-Simpson RE. Postherpetic neuralgia. J R Coll Gen Pract 1975; 25: 571–5

    PubMed  CAS  Google Scholar 

  24. Cobo LM, Foulks GN, Liesegang T, et al. Oral acyclovir in the treatment of acute herpes zoster opthalmicus. Ophthalmology 1986; 93: 763–70

    PubMed  CAS  Google Scholar 

  25. Harding SP, Lipton JR, Wells JC. Natural history of herpes zoster ophthalmicus: predictors of postherpetic neuralgia and ocular involvement. Br J Opthalmol 1987; 71: 353–8

    Article  CAS  Google Scholar 

  26. Rowbotham MC, Davies PS, Fields HL. Topical lidocaine gel relieves post herpetic neuralgia. Ann Neurol 1995; 37: 246–53

    Article  PubMed  CAS  Google Scholar 

  27. Max MB, Schafer SC, Culnane M, et al. Association of pain relief with drug side effects in post herpetic neuralgia: a single-dose study of Clonidine, codeine, ibuprofen, and placebo. Clin Pharmacol Ther 1988; 43: 363–71

    Article  PubMed  CAS  Google Scholar 

  28. Rowbotham MC, Fields HL. Topical lidocaine reduces pain in postherpetic neuralgia. Pain 1989; 38: 297–301

    Article  PubMed  CAS  Google Scholar 

  29. De Benedittis G, Besana F, Lorenzetti A. A new topical treatment for acute herpetic neuralgia and post-herpetic neuralgia: the aspirin/diethyl ether mixture: an open-label study plus a double blind controlled clinical trial. Pain 1992; 48: 383–90

    Article  PubMed  Google Scholar 

  30. Milligan KA, Atkinson RE, Schofield PA. Lignocaine-prilocaine cream in post herpetic neuralgia [letter]. BMJ 1989; 298: 253

    Article  PubMed  CAS  Google Scholar 

  31. Slow PJ, Glynn CJ, Minor B. EMLA cream in the treatment of post-herpetic neuralgia: efficacy and pharmacokinetic profile. Pain 1989; 39: 301–5

    Article  Google Scholar 

  32. Watson CP, Evans RJ, Watt VR, et al. Post-herpetic neuralgia: 208 cases. Pain 1988; 35: 289–97

    Article  PubMed  CAS  Google Scholar 

  33. Dan K, Higa K, Noda B. Nerve-block for herpetic pain. In: Fields HL, Dubner R, Cervero F, editors. Proceedings of the Fourth World Congress on Pain, Seattle. New York (NY): Raven Press, 1985: 831–8 Vol. 9. Advances in pain research and therapy

    Google Scholar 

  34. Colding A. The effect of regional sympathetic blocks in the treatment of herpes zoster: a survey of 300 cases. Acta An-aesthesiol Scand 1969; 13: 133–41

    Article  Google Scholar 

  35. Fine PG. Nerve blocks, herpes zoster and postherpetic neuralgia. In: Watson CPN, editor. Herpes zoster and postherpetic neuralgia: pain research and clinical management. Vol. 8. Amsterdam: Elsevier Science, 1993: 173–83

    Google Scholar 

  36. Kishore KR, Schafer SC, et al. Single doses of the serotonin agonists buspirone and m-chlorophenylpiperazine do not relieve neuropathic pain. Pain 1989; 37: 223–7

    Article  Google Scholar 

  37. Watson CP, Evans RJ, Reed K, et al. Amitriptyline versus placebo in post herpetic neuralgia. Neurology 1982; 32: 671–3

    Article  PubMed  CAS  Google Scholar 

  38. Watson CP, Evans RJ. A comparative trial of amitriptyline and zimelidine in postherpetic neuralgia. Pain 1985; 23: 387–94

    Article  PubMed  CAS  Google Scholar 

  39. Max MB, Schafer SC, Culnane M, et al. Amitriptyline, but not lorazepam, relieves postherpetic neuralgia. Neurology 1988; 38: 1427–32

    Article  PubMed  CAS  Google Scholar 

  40. Watson CP, Chipman M, Reed K, et al. Amitriptyline versus maprotiline in post-herpetic neuralgia: a randomized, double blind, crossover trial. Pain 1992; 48: 29–36

    Article  PubMed  CAS  Google Scholar 

  41. Kishore KR, Max MB, Schafer SC, et al. Desipramine relieves post-herpetic neuralgia. Clin Pharmacol Ther 1990; 47: 305–12

    Article  Google Scholar 

  42. Swerdlow M. Anticonvulsant drugs and chronic pain. Clin Neu-ropharmacol 1984; 7: 51–82

    CAS  Google Scholar 

  43. Swerdlow M. The treatment of ‘shooting’ pain. Postgrad Med J 1980; 56: 159–61

    Article  PubMed  CAS  Google Scholar 

  44. Killian JM, Fromm GH. Carbamazepine in the treatment of neuralgia: use of side effects. Arch Neurol 1968; 19: 129–36

    Article  PubMed  CAS  Google Scholar 

  45. Eaglstein WH, Katz R, Brown JA. The effects of early corticosteroid therapy on the skin eruption and pain of herpes zoster. JAMA 1970; 211: 1681–3

    Article  PubMed  CAS  Google Scholar 

  46. Keczkes K, Basheer AM. Do corticosteroids prevent post-herpetic neuralgia? Br J Dermatol 1980; 102: 551–5

    Article  PubMed  CAS  Google Scholar 

  47. Esmann V, Geil JP, Kroon S, et al. Prednisolone does not prevent post-herpetic neuralgia. Lancet 1987; II: 126–9

    Article  Google Scholar 

  48. Whitley RJ, Weiss H, Gnann J, et al. The efficacy of steroid and acyclovir therapy of herpes zoster in the elderly [abstract]. J Investig Med 1995; 43Suppl. 2: 252A

    Google Scholar 

  49. Portenoy RK, Duma C, Foley KM. Acute herpetic and postherpetic neuralgia: clinical review and current management. Ann Neurol 1986; 20: 651–64

    Article  PubMed  CAS  Google Scholar 

  50. Huff JC, Bean B, Balfour Jr HH, et al. Therapy of herpes zoster with oral acyclovir. Am J Med 1988; 85: 84–9

    Article  PubMed  CAS  Google Scholar 

  51. Wood MJ, Ogan PH, McKendrick MW, et al. Efficacy of oral acyclovir treatment of acute herpes zoster. Am J Med 1988; 85: 79–83

    PubMed  CAS  Google Scholar 

  52. McKendrick MW, McGill JI, White JE, et al. Oral acyclovir in acute herpes zoster. BMJ 1986; 293: 1529–32

    Article  PubMed  CAS  Google Scholar 

  53. Morton P, Thomson AN. Oral acyclovir in the treatment of herpes zoster in general practice. N Z Med J 1989; 102: 93–5

    PubMed  CAS  Google Scholar 

  54. Harding SP, Porter SM. Oral acyclovir in herpes zoster ophthalmicus. Curr Eye Res 1991; 10 (Suppl): 177–82

    Article  PubMed  Google Scholar 

  55. Tyring SK, Beutner K, Tucker BA, et al. Antiviral therapy for herpes zoster: randomized, controlled clinical trial of vala-cyclovir and famciclovir therapy in immunocompetent patients 50 years and older. Arch Fam Med 2000; 9: 863–9

    Article  PubMed  CAS  Google Scholar 

  56. Dwyer DE. Management issues I herpes zoster. Aust Fam Physician 1996; 25: 299–307

    PubMed  CAS  Google Scholar 

  57. Wood MJ, Johnson RW, McKendrick MW, et al. A randomized trial of acyclovir for 7 days or 21 days with and without prednisolone for treatment of acute herpes zoster. N Engl J Med 1994; 330: 896–900

    Article  PubMed  CAS  Google Scholar 

  58. Eide PK, Jorum E, Stubhaug A, et al. Relief of post herpetic neuralgia with the N-methyl-D-aspartic acid receptor antagonist ketamine: a double-blind, cross over comparison with morphine and placebo. Pain 1994; 58: 347–54

    Article  PubMed  CAS  Google Scholar 

  59. Levin MJ, Murray M, Rotbart HA. Immune response of elderly individuals to a live attenuated varicella vaccine. J Infect Dis 1992; 166: 253–9

    Article  PubMed  CAS  Google Scholar 

  60. Hayward A, Villanueba E, Cosyns M, et al. Varicella-zoster virus (VZV)-specific cytotoxicity after immunization of nonimmune adults with Oka Strain attenuated VZV vaccine. J Infect Dis 1992; 166: 260–4

    Article  PubMed  CAS  Google Scholar 

  61. Drago F, Rebora A. The new herpesviruses: emerging pathogens of dermatological interest. Arch Dermatol 1999; 135: 71–5

    Article  PubMed  CAS  Google Scholar 

  62. Sterling JC, Kurtz JB. Viral infections. In: Rook A, Wilkinson DS, Ebling FJB, et al., editors. Textbook of dermatology, 6th ed. Edinburgh: Blackwell Scientific, 1998: 1022–3

    Google Scholar 

  63. Lee JY. Cytomegalovirus infection involving the skin in immunocompromised hosts. Am J Clin Pathol 1989; 92: 96–100

    PubMed  CAS  Google Scholar 

  64. Boers KE. Cytomegalovirus infection. In: Freedberg IM, Eisen AZ, Austen KF, et al., editors. Fitzpatrick’s dermatology in general medicine. 5th ed. New York: McGraw-Hill, 1999: 2450–7

    Google Scholar 

  65. Horn TD, Hood AF. Cytomegalovirus is predictably present in perineal ulcers from immunocompromised patients. Arch Dermatol 1990; 126: 642–4

    Article  PubMed  CAS  Google Scholar 

  66. Eizuru Y, Minamishima Y, Hirose M, et al. Isolation of multiple cytomegalovirus strains from a patient with adult T cell leukemia. Intervirology 1990; 31: 355–8

    PubMed  CAS  Google Scholar 

  67. Aloi F, Solaroli Papotti M. Perianal cytomegalovirus ulcer in an HIV-infected patient. Dermatology 1996; 192: 81–3

    Article  PubMed  CAS  Google Scholar 

  68. Colsky AS, Jegasothy SM, Leonardi C, et al. Diagnosis and treatment of a case of cutaneous cytomegalovirus infection with a dramatic clinical presentation. J Am Acad Dermatol 1998; 38: 349–51

    Article  PubMed  CAS  Google Scholar 

  69. Pariser RJ. Histologically specific skin lesions in disseminated cytomegalovirus infection. J Am Acad Dermatol 1983; 9: 937–46

    Article  PubMed  CAS  Google Scholar 

  70. Toome BK, Bowers KE, Scott GA. Diagnosis of cutaneous cytomegalovirus infection: a review and report of a case. J Am Acad Dermatol 1991; 24: 857–63

    Article  Google Scholar 

  71. Lescher JL. Cytomegalovirus infection and the skin. J Am Acad Dermatol 1988; 18: 1333–8

    Article  Google Scholar 

  72. Suiura H, Sawai T, Miyauchi H, et al. Successful treatment of disseminated cutaneous cytomegalic inclusion disease associated with Hodgkin’s disease. J Am Acad Dermatol 1991; 24: 346–52

    Article  Google Scholar 

  73. Bhawan J, Gellis S, Ucci A, et al. Vesiculobullous lesions caused by cytomegalovirus infection in an immunocompromised adult. J Am Acad Dermatol 1984; 11: 743–7

    Article  PubMed  CAS  Google Scholar 

  74. Bournerias I, Boisnic S, Patey O, et al. Unusual cutaneous cytomegalovirus involvement in patients with acquired immunodeficiency syndrome. Arch Dermatol 1989; 125: 1243–6

    Article  PubMed  CAS  Google Scholar 

  75. Patterson JW, Broecker AH, Kornstein MJ, et al. Cutaneous cytomegalovirus infection in a liver transplant patient. Am J Dermatopathol 1988; 10: 524–30

    Article  PubMed  CAS  Google Scholar 

  76. Cole NL, Balfour Jr HH. In vitro susceptibility of cytomegalovirus isolates from immunocompromised patients to acyclovir and ganciclovir. Diagn Microbiol Infect Dis 1987; 6: 255–61

    Article  PubMed  CAS  Google Scholar 

  77. Shigeta S, Konno K, Baba M, et al. Comparative inhibitory effects of nucleoside analogues on different clinical isolates of human cytomegalovirus in vitro. J Infect Dis 1991; 163: 270–5

    Article  PubMed  CAS  Google Scholar 

  78. Andrei G, Snoeck R, Schol D, et al. Comparative activity of selected antiviral compounds against clinical isolates of human cytomegalovirus. Eur J Clin Microbiol Infect Dis 1991; 10: 1026–33

    Article  PubMed  CAS  Google Scholar 

  79. Memar OM, Tyring SK. Antiviral agents in dermatology: current status and future prospects. Int J Dermatol 1995; 34: 597–606

    Article  PubMed  CAS  Google Scholar 

  80. Drew WL. Cytomegalovirus infection in patients with AIDS. Clin Infect Dis 1992; 14: 608–15

    Article  PubMed  CAS  Google Scholar 

  81. Buhles WC, Mastre BJ, Tinker AJ, et al. Syntex Collaborative Treatment Study Group. Ganciclovir treatment of life- or sight-threatening cytomegalovirus infection experience in 314 immunocompromised patients. Rev Infect Dis 1998; 10Suppl. 3: S495–504

    Google Scholar 

  82. Garcia-Patos V, Pujol RM, Curell R, et al. Cytomegalovirus-induced cytopathic changes in skin biopsy specimens: clinicopathologic study in patients with the acquired immunodeficiency syndrome and an active extracutaneous cytomegalovirus infection. Arch Dermatol 1992; 128: 1552–3

    Article  PubMed  CAS  Google Scholar 

  83. Charthaigh MN, Crowley B, Lynch M, et al. Successful treatment of cutaneous cytomegalovirus. Int J STD AIDS 1993; 4: 52–3

    PubMed  CAS  Google Scholar 

  84. Myerson D, Hackman RC, Meyers JD. Diagnosis of cytomegalovirus pneumonia by in situ hybridization. J Infect Dis 1984; 150: 272–7

    Article  PubMed  CAS  Google Scholar 

  85. Myerson D, Hackman RC, Nelson JA, et al. Widespread presence of histologically occult cytomegalovirus. Hum Pathol 1984; 15: 430–9

    Article  PubMed  CAS  Google Scholar 

  86. Zitelli BJ, Gartner JC, Malatack JJ, et al. Pediatric liver transplantation: patient evaluation and selection, infectious complications, and life-style after transplantation. Transplant Proc 1987; 19: 3309–16

    PubMed  CAS  Google Scholar 

  87. Sandstrom EG, Byington RE, Kaplan JC, et al. Inhibition of human T-cell lymphotropic virus type III in vitro by phos-phonoformate. Lancet 1985; I: 1480–2

    Article  Google Scholar 

  88. Jabs DA, Green WR, Fox R, et al. Mortality in patients with AIDS treated with either foscarnet or ganciclovir for cytomegalovirus retinitis. N Engl J Med 1992; 326: 213–20

    Article  Google Scholar 

  89. Studies of the ocular complication of AIDS (SOCA). Research Group in Collaboration with the AIDS Clinical Trials Group: combination foscarnet and ganciclovir therapy vs. monotherapy for the treatment of relapsed cytomegalovirus retinitis patients with AIDS. Arch Ophthalmol 1996; 114: 23–33

    Article  Google Scholar 

  90. Snoeck R, Sakuma T, De Clercq E, et al. (S)-l-(3-hydroxy-2-phosphonylmethoxypropyl) cytosine, a potent and selective inhibitor of human cytomegalovirus replication. Antimicrob Agents Chemother 1988; 32: 1839–44

    Article  PubMed  CAS  Google Scholar 

  91. Kirsch LS, Arevalo JF, Chavez de la Paz E, et al. Intravitreal cidofovir (HP-MPC) treatment of cytomegalovirus retinitis in patients with acquired immune deficiency syndrome. Ophthalmology 1995; 102: 533–42

    PubMed  CAS  Google Scholar 

  92. Rahhal FM, Arevalo JF, Munguia D, et al. Intravitreal cidofovir for the maintenance treatment of cytomegalovirus retinitis. Ophthalmology 1996; 103: 1078–83

    PubMed  CAS  Google Scholar 

  93. Taskintuna I, Rahhal FM, Arevalo JF, et al. Low-dose intravitreal cidofovir (HPMPC) therapy of cytomegalovirus retinitis in patients with acquired immune deficiency syndrome. Ophthalmology 1997; 104: 1049–57

    PubMed  CAS  Google Scholar 

  94. Lalezari JP, Kuppermann BD. Clinical experience with cidofovir in the treatment of cytomegalovirus retinitis. J Acquir Immune Defic Syndr Hum Retrovirol 1997; 14Suppl. 1: S27–31

    Article  PubMed  CAS  Google Scholar 

  95. Lalezari JP, Drew WL, Glutzer E, et al. (S)-l-[3-hydroxy-2-(phosphonylmethoxyl)propyl]cytosine(cidofovir): results of a phase I/II study of a novel antiviral nucleotide analogue. J Infect Dis 1995; 171: 788–96

    Article  PubMed  CAS  Google Scholar 

  96. Villarreal EC. Current and potential therapies for the treatment of herpesvirus infections. Prog Drug Res 2001; 56: 77–120

    Article  PubMed  CAS  Google Scholar 

  97. Cotton DWK, Cooper C, Barrett DF, et al. Severe atypical molluscum contagiosum infection in an immunocompromised host. Br J Dermatol 1987; 116: 871–6

    Article  PubMed  CAS  Google Scholar 

  98. Katzman M, Carey JT, Elmets CA, et al. Molluscum contagiosum and the acquired immunodeficiency syndrome: clinical and immunological details of two cases. Br J Dermatol 1987; 116: 131–8

    Article  PubMed  CAS  Google Scholar 

  99. Schwartz JJ, Myskowski PL. Molluscum contagiosum in patients with HIV infection: a review of 27 patients. J Am Acad Dermatol 1992; 27: 583–8

    Article  PubMed  CAS  Google Scholar 

  100. Meadows KP, Tyring SK, Pavia AT, et al. Resolution of recalcitrant molluscum contagiosum lesions in human immunodeficiency virus-infected patients treated with cidofovir. Arch Dermatol 1997; 133: 987–90

    Article  PubMed  CAS  Google Scholar 

  101. Davies EG, Thrasher A, Lacey K, et al. Topical cidofovir for severe molluscum contagiosum. Lancet 1999; 353: 2042

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

No sources of funding were used to assist in the preparation of this manuscript. The authors have no conflicts of interest that are directly relevant to the content of this manuscript.

Author information

Authors and Affiliations

  1. Department of Dermatology, St. Luke’s-Roosevelt Hospital Center, New York, USA

    Rashmi Bansal, William D. Tutrone &  Jeffrey M. Weinberg

Authors
  1. Rashmi Bansal
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. William D. Tutrone
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jeffrey M. Weinberg
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jeffrey M. Weinberg.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bansal, R., Tutrone, W.D. & Weinberg, J.M. Viral Skin Infections in the Elderly. Drugs Aging 19, 503–514 (2002). https://doi.org/10.2165/00002512-200219070-00004

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002512-200219070-00004

Keywords

Search

Navigation